Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.

NCT00174304

Last updated date
Study Location
Pfizer Investigational Site
Salzburg, , A-5020, Austria
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension, Hyperlipidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Treated or untreated subjects with concurrent hypertension and dyslipidemia with BP and LDL-C not at target according to governing guidelines

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- High liver enzymes

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hypertension, HyperlipidemiaComparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia
NCT00174330
  1. Beijing, Beijing
  2. Guangzhou, Guangdong
  3. Guangzhou, Guangdong
  4. Guangzhou, Guangdong
  5. Nanjing, Jiangsu
  6. Shen Yang, Liaoning
  7. Shanghai, Shanghai
  8. Hangzhou, Zhejiang
  9. Beijing,
  10. Beijing,
  11. Beijing,
  12. Shanghai,
  13. Shanghai,
  14. Shanghai,
  15. Tianjin,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Hypertension, HyperlipidemiaOpen Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.
NCT00174304
  1. Salzburg,
  2. St. Poelten,
  3. Vienna,
  4. Wels,
  5. Bierbeek,
  6. Braine-L'Alleud,
  7. Brugge,
  8. De Pinte,
  9. Gozée,
  10. Seraing,
  11. Wemmel,
  12. Wilrijk,
  13. Zedelgem,
  14. Helsinki,
  15. Kuopio,
  16. Kuopio,
  17. Oulu,
  18. Oulu,
  19. Tampere,
  20. Turku,
  21. Turku,
  22. Vantaa,
  23. Heraklion, Crete
  24. Athens,
  25. Ioannina,
  26. Larissa,
  27. Melissia,
  28. Pireaus,
  29. Rio, Patra,
  30. Thessaloniki,
  31. Thessaloniki,
  32. Budapest,
  33. Budapest,
  34. Budapest,
  35. Debrecen,
  36. Kecskemét,
  37. Miskolc,
  38. Mosonmagyaróvár,
  39. Pécs,
  40. Szekszárd,
  41. Gorey, Wexford
  42. New Ross, Wexford
  43. Vimercate, (mi)
  44. Somma Lombardo, (va)
  45. San Sisto, PG
  46. Mestre, VE
  47. Asti,
  48. Bologna,
  49. Bologna,
  50. Bologna,
  51. Bolzano,
  52. Brescia,
  53. Catania,
  54. Catania,
  55. Chieti,
  56. Ferrara,
  57. Firenze,
  58. Foggia,
  59. Genova,
  60. Grosseto,
  61. Napoli,
  62. Novara,
  63. Palermo,
  64. Palermo,
  65. Perugia,
  66. Potenza,
  67. Prato,
  68. Roma,
  69. Salerno,
  70. Sassari,
  71. Siena,
  72. Torino,
  73. Venezia,
  74. Guilhufe - Pnf, Penafiel
  75. Matosinhos, Sra. da Hora
  76. Coimbra,
  77. Faro,
  78. Leiria,
  79. Lisboa,
  80. Lisboa,
  81. Lisbon,
  82. Porto,
  83. Porto,
  84. S. Martinho Do Bispo,
  85. Viana Do Castelo,
  86. Izola,
  87. Ljubljana,
  88. Maribor,
  89. San Sebastian, Guipuzcoa
  90. Reus, Tarragona
  91. Barcelona,
  92. Barcelona,
  93. Madrid,
  94. Madrid,
  95. Baden, AG
  96. Bern, BE
  97. Basel, BS
  98. St. Gallen, SG
  99. Münsterlingen, TG
  100. Lugano, TI
  101. Lausanne, VD
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Hypertension, HyperlipidemiaAmlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
NCT00143234
  1. Buenos Aires,
  2. Buenos Aires,
  3. Buenos Aires,
  4. Buenos Aires,
  5. Buenos Aires,
  6. St. Leonards, New South Wales
  7. Southport, Queensland
  8. Woolloongabba, Queensland
  9. Heidelberg, Victoria
  10. Melbourne, Victoria
  11. Prahran, Victoria
  12. Fremantle, Western Australia
  13. Belo Horizonte, MG
  14. Belo Horizonte, MG
  15. Belo Horizonte, MG
  16. Recife, PE
  17. Botucatu, SP
  18. Campinas, SP
  19. Ribeirao Preto, SP
  20. Sao Paulo, SP
  21. São Paulo, SP
  22. Santiago, Región Metropolitana
  23. Santiago, RM
  24. Guatemala,
  25. Pokfulam Road,
  26. Sai ying Pun,
  27. Hyderabad, Andhra Pradesh
  28. Hyderabad, Andhra Pradesh
  29. Bangalore, Karnataka
  30. Mumbai, Maharashtra
  31. Pune, Maharashtra
  32. Mumbai, Nagpada Junction
  33. New Delhi,
  34. New Delhi,
  35. New Delhi,
  36. Jakarta,
  37. Jakarta,
  38. Surabaya,
  39. Jerusalem,
  40. Jerusalem,
  41. Rehovot,
  42. Tel Aviv,
  43. Tel Hashomer,
  44. Amman,
  45. Amman,
  46. Seo-gu, Busan
  47. Jung-gu, Daegu
  48. Dong-gu, Kwangji
  49. Anyang-city, Kyungki-do
  50. Guri-City, Kyungki-do
  51. Gangnam-gu, Seoul
  52. Yongdeungpo-gu, Seoul
  53. Seoul,
  54. Seoul,
  55. Seoul,
  56. Sasat,
  57. Beirut,
  58. Kubang Kerian, Kelantan
  59. Seremban, Negeri Sembilan
  60. Kuching, Sarawak
  61. Kuala Lumpur,
  62. Kuala Lumpur,
  63. Mexico, D.F
  64. Aguascalientes,
  65. Metepec,
  66. Mexico,
  67. Puebla,
  68. San Luis Potosi,
  69. Casablanca,
  70. Peshawar, N.w.f.p.
  71. Faisalabad, Punjab
  72. Islamabad, Punjab
  73. Lahore, Punjab
  74. Lima,
  75. San Juan, Metro Manila
  76. Phippine General Hospital, Taft Avenue, Manila City
  77. Filinvest, Alabang,
  78. Manila,
  79. Quezon City,
  80. Quezon City,
  81. Al-Khobar,
  82. Riyadh,
  83. Riyadh,
  84. Singapore,
  85. Singapore,
  86. Worcester, Cape Province
  87. Arcadia, Pretoria, Gauteng
  88. Midrand, Johannesburg, Gauteng
  89. Sunnyside, Pretoria, Gauteng
  90. Chatsworth, Natal
  91. Cape Town,
  92. Cape Town,
  93. Cape Town,
  94. Gauteng,
  95. Kwa-Zulu Natal,
  96. Niao-Sung Hsiang, Kaohsiung
  97. Guei-Shan Shiang, Tau-Yuan Shian
  98. Changhua City,
  99. Taipei,
  100. Taipei,
  101. Taipei,
  102. Khet Rajathevee, Bangkok
  103. Bangkok,
  104. Chiang Mai,
  105. Tunis,
  106. Cebeci, Ankara
  107. Sihhiye, Ankara
  108. Haydarpasa, Istanbul
  109. Alsancak, Izmir
  110. Talas, Kayseri
  111. Adana,
  112. Antalya,
  113. Diyarbakir,
  114. Istanbul,
  115. Abu Dhabi,
  116. Dubai,
  117. Sharjah,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.
Official Title  ICMJE An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)
Brief Summary To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Hypertension
  • Hyperlipidemia
Intervention  ICMJE Drug: Amlodipine/atorvastatin single pill
Study Arms  ICMJE Not Provided
Publications * Richard Hobbs FD, Gensini G, John Mancini GB, Manolis AJ, Bauer B, Genest J, Feldman RD, Harvey P, Jenssen TG, da Silva PM; JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil. 2009 Aug;16(4):472-80. doi: 10.1097/HJR.0b013e32832b63f5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 9, 2005)
1120
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE September 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Treated or untreated subjects with concurrent hypertension and dyslipidemia with BP and LDL-C not at target according to governing guidelines

Exclusion Criteria:

  • High liver enzymes
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   Belgium,   Finland,   Greece,   Hungary,   Ireland,   Italy,   Portugal,   Slovenia,   Spain,   Switzerland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00174304
Other Study ID Numbers  ICMJE A3841029
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP